DOACs, CAD, and PCI: How to Treat?

The goal of this activity is to learn about the latest clinical data and guidelines supporting the use of factor Xa inhibitor therapy for treatment of patients with coronary artery disease (CAD) who are undergoing percutaneous coronary intervention (PCI).
 
Educational Partner: Medscape, LLC
 
Medium: Online Presentation
 
Commercial Support: Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This activity is intended for cardiologists, primary care physicians, and surgeons.

Learning Objectives

Upon completion of this activity, participants will:
 
  • Have increased knowledge regarding the
    • Clinical data supporting the use of factor Xa inhibitor therapy for treatment of patients with CAD who are undergoing PCI
    • Latest recommendations on the use of antithrombotic therapy in patients with CAD who are undergoing PCI
Additional information
ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
For more information, please contact:
CME Coordinator Contact Name: 
Medscape
CME Coordinator Contact Email: 
AttachmentSize
Postcard472.68 KB
Summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Activity opens: 
02/26/2020
Activity expires: 
02/26/2021
MODERATOR
Deepak L. Bhatt, MD, MPH
Professor of Medicine
Harvard Medical School
Executive Director of Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Boston, Massachusetts, United States
 
PANELIST
Roxana Mehran, MD
Professor of Medicine
Director of Interventional
Cardiovascular Research and Clinical Trials
Icahn School of Medicine at Mount Sinai
New York, New York
 
COURSE REVIEWER
Matthew Sorrentino, MD FACC FAHA
Vice Chair for Clinical Operations
Department of Medicine
Section of Cardiology
University of Chicago Medicine
 
 

Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Accreditation Statements
 
Developed through a collaboration between the University of Chicago Medicine and Medscape Education.
 
Physician credit
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professions Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Registration: To view this activity, you will need to visit Medscape's website.
Click here to view the activity or if you are logged in click on the "Complete Activity" button!
 
Please login or create an account to proceed.